Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

Meanwhile, Relyvrio has already been conditionally approved in Canada under the Albrioza brand name, although it has not yet launched there, as Amylyx remains in pricing negotiations.

Amid a broader market selloff on Monday, Mizuho Securities upgraded the Cambridge, Massachusetts-based biotech Amylyx ...

Amylyx Pharmaceuticals ... Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge ...

The company expects early cohort data this year from the trial assessing the calpain-2-targeted antisense oligonucleotide therapy.

Amylyx Pharmaceuticals ... The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2024 financial results on Tuesday ...